The groundbreaking success of the copyright undeniably reshaped the pharmaceutical landscape, but investing in companies heavily reliant on unbranded versions presents a challenging picture. Although early earnings were substantial, the expiration of patents and the appearance of cheaper alternatives have diminished sales. Thus, a thorough evaluati